Vorinostat and Bortezomib in Treating Patients With Metastatic or Unresectable Solid Tumors
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This phase I trial is studying the side effects and best dose of vorinostat and bortezomib in
treating patients with metastatic or unresectable solid tumors. Drugs used in chemotherapy,
such as vorinostat, work in different ways to stop the growth of tumor cells, either by
killing the cells or by stopping them from dividing. Bortezomib may stop the growth of tumor
cells by blocking some of the enzymes needed for cell growth. Giving vorinostat together with
bortezomib may kill more tumor cells.